

Breakfast with the Investigators: Exploring the Role of PARP Inhibition in the Management of Ovarian Cancer**THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. Which of the following statements is correct regarding recommended BRCA testing for patients with ovarian cancer?**
 - A patient with a negative result from BRCA germline testing does not need subsequent tumor testing to establish whether she has a somatic BRCA mutation
 - A patient with a negative result from BRCA germline testing needs subsequent tumor testing to establish whether she has a somatic BRCA mutation**
- 2. The ongoing Phase III PRIMA trial is investigating the efficacy and safety of maintenance therapy with the PARP inhibitor _____ for patients who experience a complete or partial response to front-line platinum-based chemotherapy for advanced-stage ovarian cancer.**
 - Olaparib
 - Rucaparib
 - Niraparib**
 - Veliparib
- 3. Results of the Phase III SOLO-1 trial of maintenance olaparib versus placebo for patients with newly diagnosed advanced-stage ovarian, fallopian tube or primary peritoneal cancer and a deleterious or suspected deleterious BRCA mutation who attained a complete or partial response to first-line platinum-based therapy demonstrated an improvement in progression-free survival (PFS) with olaparib in which of the prespecified subgroups?**
 - Patients younger than 65 years
 - Patients with Stage III disease
 - Patients in complete response after chemotherapy
 - All prespecified patient subgroups**
- 4. The ongoing Phase III ATHENA trial is evaluating _____, nivolumab or the combination as first-line maintenance therapy for patients with newly diagnosed, advanced-stage epithelial ovarian, fallopian tube or primary peritoneal cancer.**
 - Niraparib
 - Olaparib
 - Rucaparib**
- 5. Which of the following PARP inhibitors is FDA approved as maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who experience complete or partial response to platinum-based therapy, regardless of BRCA mutation status?**
 - Olaparib
 - Rucaparib
 - Niraparib
 - All of the above**
 - Both a and b
 - Both a and c